Table 3 Aspirin trials with colorectal adenoma as the primary endpoint

From: Progress in preventive therapy for cancer: a reminiscence and personal viewpoint

Study

Arm

Treatment duration (years)

Follow-up (years)

N (participants)

N(cases)

Relative risk (95% CI)

Baron et al.52

85 mg

3

3

377

140

0.81 (0.69–0.96)

325 mg

366

160

0.96 (0.81–1.19)

Placebo

372

Sandler et al.53

325 mg

1

2.5

259

43

0.65 (0.46–0.91)

Placebo

  

258

60

APACC trial54

160/300 mg

4

5

126

38

0.73 (0.52–1.04)

Placebo

112

46

Back to article page